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Overexpression of DNMT3b target 
genes during Enteric Nervous 
System development contribute to 
the onset of Hirschsprung disease
Leticia Villalba-Benito1,2, Ana Torroglosa1,2, Raquel María Fernández1,2,  
Macarena Ruíz-Ferrer1,2, María José Moya-Jiménez3, Guillermo Antiñolo1,2 & Salud Borrego1,2
Hirschsprung disease (HSCR) is attributed to a failure of neural crest cells (NCCs) to migrate, 
proliferate, differentiate and/or survive in the bowel wall during embryonic Enteric Nervous System 
(ENS) development. ENS formation is the result from a specific gene expression pattern regulated 
by epigenetic events, such DNA methylation by the DNA methyltransferases (DNMTs), among other 
mechanisms. Specifically, DNMT3b de novo methyltransferase is associated with NCCs development 
and has been shown to be implicated in ENS formation and in HSCR. Aiming to elucidate the 
specific mechanism underlying the DNMT3b role in such processes, we have performed a chromatin 
immunoprecipitation coupled with massively parallel sequencing analysis to identify the DNMT3B 
target genes in enteric precursor cells (EPCs) from mice. Moreover, the expression patterns of those 
target genes have been analyzed in human EPCs from HSCR patients in comparison with controls. 
Additionally, we have carried out a search of rare variants in those genes in a HSCR series. Through this 
approach we found 9 genes showing a significantly different expression level in both groups. Therefore, 
those genes may have a role in the proper human ENS formation and a failure in their expression 
pattern might contribute to this pathology.
Hirschsprung disease (HSCR, OMIM 142623) is a human developmental disorder, affecting 1:5,000 newborns. 
HSCR is characterized by the lack of enteric ganglia along the distal bowel, which causes a severe intestinal 
dysfunction1. The disease appears either sporadically or on a familial basis and may be associated with other 
developmental defects. Such aganglionosis observed in HSCR is due to failures in the proliferation, migration, 
differentiation and/or survival of the enteric precursors derived from neural crest cells (NCCs) which avoid 
a proper colonization of the gastrointestinal tract during embryonic development of Enteric Nervous System 
(ENS). HSCR phenotype is classified based on the length of the aganglionic region as: short-segment (S-HSCR) 
which includes patients with aganglionosis as far as the splenic flexure, long-segment (L-HSCR) in which agan-
glionosis extends beyond the splenic flexure and total colonic aganglionosis forms (TCA)2.
ENS development is a complex process that is regulated by a specific gene expression pattern at each stage dur-
ing embryogenesis and any change in this process leads to serious consequences as observed in HSCR3. HSCR is 
a disorder with complex genetic basis, whose etiology is frequently due to the presence of several genetic variants 
acting in an additive or multiplicative manner2, 4. In this sense, the RET proto-oncogene (OMIM 164761) is the 
main gene associated with HSCR although up to another 40 different genes have been also related to the disease5, 
6. RET coding rare mutations account for up to 50% of familial cases and for 10–20% of sporadic cases, while 5% 
of cases are due to mutations in genes other than RET. Therefore, it is necessary to continue with the search of 
additional genes to better delineate the HSCR etiology.
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One of the well established mechanisms in the regulation of gene expression is epigenetics. Epigenetic mech-
anisms are acquiring increasing evidence of playing a major role in the onset of HSCR7, 8. Different epigenetic 
mechanisms are known, such as DNA methylation by the DNA methyltransferases (DNMT1, DNMT3a and 
DNMT3b). DNMT1 represents the maintenance methyltransferase and DNMT3a and 3b act as de novo meth-
yltransferases establishing the methylation pattern during embryogenesis. It has been shown that both de novo 
methyltranferases are essential for the suitable NCCs development9–11. DNMT3b has been described as the meth-
yltransferase that regulates the initial steps of progenitor cell differentiation during embryogenesis12. In addition, 
it has been shown that the expression of DNMT3b is lower in EPCs from HSCR patients compared with controls 
and this aberrant expression leads to a decrease of the global DNA methylation7, which may be contributing to an 
inappropriate gene expression pattern and to the onset of this pathology.
Therefore, we have performed a Chromatin immunoprecipitation coupled with massively parallel sequencing 
analysis (ChIP-seq) on mouse EPCs for the identification of DNMT3b target genes and then we have compared 
their expression levels in postnatal human EPCs from HSCR patients and controls. In addition, we have searched 
for rare variants into those target genes on whole exome sequences from a set of HSCR patients.
Results
Identification of DNMT3b-targets in mouse EPCs. ChIP-seq assay was performed in 3 different pools 
in order to identify a set of DNMT3b target genes in mouse EPCs. A total of 23,5 × 106 (94%) reads passed the 
filters established by the MiSeq System and 12 × 106 (51%) mapped reads were obtained. Two different analyses 
were subsequently used in order to select a number of reliable genes as targets of DNMT3b. Both methodological 
approaches are shown in Fig. 1 and described in detail in the methods section. Through the methods 1 and 2 we 
identified 924 and 152 genomic regions significantly enriched (peaks) respectively. In general, the analysis of the 
peaks distribution revealed that DNMT3b binding sites are preferentially intergenic and intronic regions (Fig. 2). 
Overall, taking into account the results from the 2 methods, a total of 15 different genes were obtained as potential 
Dnmt3b-targets (6 of them detected with both approaches). In addition we also identified another 12 genes corre-
sponding to some of the observed peaks that had not passed any of the established filters but had been previously 
related with either the NCCs and/or the ENS development or with HSCR (Table 1).
Genes selected for the assessment of their potential implication in HSCR. To further investi-
gate if the 27 genes selected as potential Dnmt3b target genes in mouse have any kind of association with the 
onset of HSCR, we searched the Human Orthologs of these genes in the Mouse Genome Informatics data-
base (MGI). Specifically, the Rn45s gene was not found in MGI but we could find the RN45S gene, also known 
as RNA45S5, in the GeneCards Human Gene Database. The Human Orthologs of some target genes are still 
unknown and for that reason we searched their homologous sequence using the Basic Local Alignment Search 
Tool (BLAST) and selected those human genes with the highest similarity (Table 2). The human pseudogene RP11 
220D10.1 appeared as the region with the highest similarity (82.44%) with the mouse gene 4933422A05Rik. The 
Figure 1. Prioritization and selection of DNMT3b-targets. Diagram showing both methodological approaches 
used for the selection of DNMT3b target genes.
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Figure 2. Peak distribution obtained in DNMT3b ChIP-seq assay. Diagram showing the peaks distribution, in 
which it is revealed that DNMT3b binding sites are preferentially intergenic and intronic regions.
ANALYSIS METHODS GENES
Shared genes in 1 & 2 method (6 genes)
Rn45s
Dnmt3b target genes
Dpp9
Mydgf
Myo7a
Ano2
Gm17644
Genes present in 1 or 2 method (9 genes)
Sulf1
2210408I21Rik
Ly75
Kpna1
4933422A05Rik
Chl1
Cyr61
Gphn
Bbx
Genes with functional role in Neural Development (but 
they did not pass some of the filters established) (12 genes)
Rab10os
Drg1
Eif4enif1
Sfi1
Ppp2r2b
Dopey2
Smo
Litaf
Cdk5rap2
Limd1
4921504E06Rik
Tmem125
Table 1. Selected genes in mouse-NLBS.
Genes (mice) Ortholog genes in Human
Rn45s RNA45S5
Gm17644 LINC01603* (79,27%)
2210408I21Rik KIAA0825
Rab10os RAB10* (96,28%)
4921504E06Rik C10ORF67
Table 2. Homologous genes in Human. *Orthologs unknown, genes selected by sequence similarity (%) 
through BLAST tool.
www.nature.com/scientificreports/
4SCIeNtIFIC RepoRts | 7: 6221 | DOI:10.1038/s41598-017-06539-8
pseudogenes are the result of reverse mRNAs transcripts from original genes that are integrated into a new region 
in the genome. Therefore, the analysis of these genomic regions are complicated and we decided to eliminate 
RP11 220D10.1 from de analysis. At this point, we counted 26 genes in humans.
In terms of DNMT3b target genes we also found it interesting to investigate about their signaling pathways 
and interaction with other genes as well as about their function. With this aim, we used the Ingenuity Pathway 
Analysis (IPA) powerful tool, which enabled us to associate physiological functions and diseases to our target 
genes and obtain a high level overview of their biological interactions described so far. Based on all the genetic 
interactions obtained for each target gene with the parameters established in the IPA (see Supplementary Fig. S1), 
we decided to select an additional group of genes (EED, STAT3, NEUROG1, ADAM8, NEDD4 and NEDD4L), 
because either their interaction with more than one DNMT3b target gene or their function in “cellular develop-
ment”. Therefore, we finally considered a total of 32 genes to perform an analysis of their expression patterns in 
human EPCs (Table 3).
Analysis of differential expression patterns in HSCR vs Controls EPCs. To evaluate the possible 
involvement in HSCR of the 32 genes previously selected, we performed a differential gene expression study in 
human EPCs cultured as Neurosphere-like Bodies (NLBs) from HSCR patients compared with controls. As a 
result 12 genes showed a positive expression in human EPCs (see Supplementary Table S1). When we compared 
their gene expression pattern in EPCs from HSCR patients versus controls, 9 of the genes (KPNA1, EED, SULF1, 
CDK5RAP2, BBX, DRG1, RAB10, MYDGF and RNA45S5) were found to be significantly up-regulated in the 
HSCR group (p value ≤ 0,05) (Fig. 3). None of such target genes overlapped with those reported from prior 
Genome Wide Association/Expression Studies in the context of HSCR.
Identification of rare variants possibly associated to HSCR in DNMT3b-targets and other 
related genes expressed in human EPCs. To assess whether the 14 selected genes shown to be expressed 
in human EPCs could contribute to HSCR susceptibility through rare sequence variants, we analysed the whole 
exome sequencing (WES) data from 56 HSCR patients13. A total of 12 heterozygous rare variants (10 SNVs and 2 
small deletions) distributed among 5 of the 15 candidates were identified in 10 patients. Nine of the variants were 
located within the coding region and 3 were in untranslated regions (UTR). All of them were confirmed by Sanger 
sequencing and details are shown in Table 4.
The analysis revealed just one familial HSCR case carrying a rare variant in one of the genes, but showing no 
segregation with the phenotype since it was not present in the other affected member of the family and it had 
been inherited from his unaffected mother. The remaining variants were identified in sporadic HSCR cases, most 
of them with a short-segment phenotype. All these rare variants were inherited from one of their parents and 
occasionally they appeared in unaffected siblings. Interestingly, we observed that two of these sporadic patients 
carried two different rare variants inherited from each parent. One of them was a female L-HSCR patient carrying 
both variants in two different genes, SULF1 and CDK5RAP2, while the other one was a male S-HSCR patient with 
two different rare variants in CDK5RAP2.
Discussion
There are growing evidences indicating that epigenetic mechanisms have an essential role for the proper ENS 
and NCCs development8. In this sense, the de novo methyltransferase DNMT3b has been associated with HSCR7 
and, therefore, we have focused in the identification of DNMT3b target genes to elucidate the pathways and genes 
which are regulated by this methyltranferase. Taking into account that in the context of rare disorders such as 
HSCR the recruitment of a high number of patients is really difficult, we designed an indirect experiment in EPCs 
from mouse to identify the possible Dnmt3b target genes by ChIP-seq, since with this kind of samples we have 
no limitations regarding the minimal starting quantity required for the assays. As a result, we observed that the 
majority of Dnmt3b binding sites were located in intronic and intergenic regions, from which a priori it is not 
easy to predict functional consequences. However, there are already some studies that have identified differen-
tially methylated regions (DMRs), not exclusively in intragenic but also in intergenic regions, and proposed these 
non-promoter CpG islands as regulatory elements14–16. The roles of this DNA methylation remain unclear as well 
as how these regions are established, maintained, and function. Nevertheless, increasingly more studies are iden-
tifying the methylation of these regions as regulators of gene expression17.
Based in the results obtained in mouse, to continue with the investigation of the role of the resulting target 
genes in HSCR, we performed a differential expression study in human EPCs from HSCR patients and controls. 
It is worthy to note that all the genes observed to be differentially expressed in HSCR patients versus controls are 
up-regulated in the first group, which fits with the lower global DNA methylation due to the decreased expression 
of DNMT3b described in HSCR patients7. In addition, we carried out a search of rare variants in those genes in a 
HSCR series. Interestingly, the finding of rare variants with incomplete penetrance in 5 of these genes in our series 
of patients, suggest that they may also be contributing to the HSCR phenotype. Moreover, most of those genes 
have been related either directly or indirectly to NCCs development, ENS and Central Nervous System (CNS) 
formation, neurogenesis and/or HSCR. In the case of MYDGF, its involvement in those processes had not been 
described to date. This gene encodes for the Myeloid Derived Growth Factor, which promotes cardiac myocyte 
survival and angiogenesis18. Such cell processes are also essential for the correct ENS formation at the neuronal 
level.
KPNA1 encodes for karyopherin alpha1, a protein that belongs to the importin-alpha family that is implicated 
in the STAT3 transport into the cell nuclei19. We have observed that STAT3 is expressed in human EPCs and this 
signal transducer and transcription activator has been related with the maintenance of the NCCs in an undiffer-
entiated state during development, promoting their differentiation when it is down-regulated20. Moreover, STAT3 
pathway activation is triggered by the phosphorylation of the RET receptor21, which is encoded by the main 
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gene involved in HSCR described so far2, 5. On the other hand, EED (Embryonic Ectoderm Development) is an 
epigenetic regulator that belongs to Polycomb repressive proteins and controls neural crest gene expression dur-
ing NCCs specification and migration22. We decided to include EED in this study because Foust et al. described 
the interaction between EED and KPNA123, also predicted by the IPA tool. Interestingly, we have observed that 
this gene is expressed in human EPCs and it is also found to be significantly up-regulated in EPCs from HSCR 
patients versus controls.
With respect to SULF1, it encodes for an endosulphatase that regulates the sulphation pattern of Heparan 
Sulphate Proteoglycans (HSPG). It has been described that SULF1 is required for RET/GDNF interaction24. 
Activation of the RET pathway through GDNF promotes enteric NCCs proliferation and differentiation, essential 
for ENS formation and this pathway has been largely related with the onset of HSCR. Regarding BBX, it encodes 
for a transcription factor member of the SOX family. Several transcription factors belonging to this family have 
been associated with neural stem cells maintenance (SOX9)25, NCCs development (SOX2 and SOX8) or HSCR 
(SOX10 and SOX2)26–28. Specifically, BBX is expressed in progenitor cells, regulates their self-renewal capacity and 
prevents their differentiation during CNS development29. To finish with this group of genes, we should highlight 
DRG1 which maps to 22q12^q13.1 region30. It has been shown in humans that this locus is a susceptibility region 
for HSCR31. DRG1 encodes for a GTPase highly expressed during CNS embryogenesis32.
On the other hand, we have identified CDK5RAP2 and RAB10, both genes implicated in neurogenesis which 
is an important process for the ENS formation33. CDK5RAP2 encodes for a CDK5 regulatory subunit associated 
protein 2 and is essential for the correct mitotic cell cycle. Mice with an in-frame deletion in CDK5RAP2 show 
microcephaly and proliferative and survival defects in neurons during development. These mice also show smaller 
ganglionic eminences in comparison with the wild-type phenotype34. It has also been demonstrated that a loss of 
ASSAY GENE NAME SELECTION
TaqMan® Array Plate
DPP9 Dipeptidyl Peptidase 9
DNMT3b Target genes
MYO7A Myosin VIIA
CDK5RAP2 CDK5 Regulatory Subunit Associated Protein 2
MYDGF Myeloid-Derived Growth Factor
SULF1 Sulfatase 1
ANO2 Anoctamin 2
CHL1 Cell Adhesion Molecule L1 Like
LIMD1 LIM Domains Containing 1
CYR61 Cysteine Rich Angiogenic Inducer 61
GPHN Gephyrin
SFI1 SFI1 Centrin Binding Protein
DOPEY2 Dopey Family Member 2
DRG1 Developmentally Regulated GTP Binding Protein 1
SMO Smoothened Frizzled Class Receptor
C10ORF67 Chromosome 10 Open Reading Frame 67
TMEM125 Transmembrane Protein 125
KIAA0825 KIAA0825
LY75 Lymphocyte Antigen 75
BBX Bobby Sox Homolog
EIF4ENIF1 Eukaryotic Translation Initiation Factor 4E Nuclear Import Factor 1
PPP2R2B Protein Phosphatase 2 Regulatory Subunit B. Beta
KPNA1 Kayopherin Subunit Alpha 1
LITAF Lipopolysaccharide Induced TNF Factor
RAB10 RAB10. Member RAS Oncogene Family
EED Embryonic Ectoderm Development
Related genes of DNMT3b 
target genes established by IPA
NEDD4 Neural Precursor Cell Expressed Developmentally Down-Regulated 4. E3 Ubiquitin Protein Ligase
NEDD4L Neural Precursor Ceel Expressed, Developmentally Down-Regulated 4-Like. E3 Ubiquitin Protein Ligase
STAT3 Signal Transducer and Activator of Transcription 3
NEUROG1 Neurogenin 1
ADAM8 ADAM Metallopeptidase Domain 8
S18 Endogenous control
SYBR Green
LINC01603 Long Intergenic NON-Protein Coding RNA 1603
DNMT3b Target genesRNA45S5 RNA, 45 S Pre-Ribosomal 5
GAPDH Endogenous control
Table 3. Genes included in the differential expression study in human NLBs.
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CDK5RAP2 function results in premature cell cycle exit, leading to a premature differentiation into neurons33. It 
is worth mentioning that two different CDK5RAP2 rare variants (c.2482A > G:p.Lys828Glu and c.1406A > G:p.
Asn469Ser) were identified in the same patient. In addition, we identified another HSCR patient who carries the 
variant p.Thr360Ile in CDK5RAP2 and also the variant c.2155_2157delAAC:p.Asn720del in SULF1. This could 
suggest that these variants here identified may be contributing to the final phenotype, reinforcing the possible role 
of CDK5RAP2 and SULF1 in HSCR phenotype.
Regarding RAB10, it is a member of small GTPases RAS oncogene family. This gene is involved in early 
embryogenesis35 and its role in axon development and dendrite growth, essential for the proper neuronal net-
works formation in CNS, has been also shown36, 37.
Also of interest RNA45S5 is a non coding RNA and it is a precursor for the 18S, 5.8S and 28S rRNA subunits. 
Sánchez-Martín et al. showed that Rn45s is expressed in postnatal mice CNS and it is regulated by methylation 
level38. On the other hand, TCOF1 has been identified as a gene which plays a central role in the regulation 
of ribosome biogenesis and pre-ribosomal processing. Loss of function mutations in this gene cause Treacher 
Collins syndrome (TCS, OMIM 154500), that it is characterized by abnormal cranial neural crest cells, survival, 
migration and differentiation during development39. Therefore, there are evidences suggesting that the genes 
related with the ribosome biogenesis have a role in NCCs development.
In summary, we have performed a study on mouse EPCs which has allowed us to identify for the first time 
a set of DNMT3b target genes with a potential role in ENS development. Subsequently, we have analyzed the 
Figure 3. Differential gene expression in HSCR-NLBs versus Control-NLBs. (a) The Heat map was generated 
using DataAssist v3.0 software (Life Technologies) and it represents the messenger RNA expression levels of 
9 genes expressed in colon tissue from HSCR patients and controls. Genes were hierarchically clustered by 
Pearson correlation coefficient using average linkage. The color scale, representing ΔCt, is shown on the right 
side. Green indicates genes with relatively decreased expression in HSCR, whereas red indicates genes with 
relatively increased expression in HSCR compared with the controls. Ct, cycle threshold; Hirschsprung patiens 
(H); Control (C). (b) Table showing the variations in the gene expression levels in the NLBs from HSCR patients 
compared with Controls.
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implication of these target genes in human EPCs, and this approach has led us to identify that their expression is 
regulated by DNMT3b-methylation in these cells during ENS formation. Therefore epigenetic mechanisms have 
acquired a relevant role in the HSCR context. Accordingly, we may conclude that these genes could be implicated 
in the proper ENS formation and failures at this regulation level may contribute to trigger the onset of this pathol-
ogy. Therefore, the role of such genes must be further analyzed in detail in the context of HSCR. It is worthy to 
note that our findings support the convenience to focus the search of mechanisms involved in HSCR onset from 
an epigenetic point of view together with the conventional approaches.
Material and Methods
Culture of enteric neurosphere-like bodies (NLBs) from human and mouse. EPCs were obtained 
from human postnatal tissues of ganglionic gut in 14 sporadic non-related patients diagnosed with isolated HSCR 
(L-HSCR = 2; S-HSCR = 12, male: female = 11:3), as well as in 5 patients with other gastrointestinal disorders 
undergoing gut resection surgery at our Hospital that were used as controls (male:female = 3:2). For both HSCR 
patients and control individuals, age ranged from 3 months to 3 years. The written informed consent for surgery, 
clinical and molecular genetic studies was obtained from all the human participants or their guardians. The study 
was approved by the Ethics Committee for clinical research of the University Hospital Virgen del Rocío (Seville, 
Spain) and complies with the tenets of the declaration of Helsinki.
EPCs were extracted from ganglionic bowels of both CD-1 7days-aged mice and humans, and were grown 
as Neuroesphere-like bodies (NLBs) as described elsewhere7. All the procedures involving mice were per-
formed in accordance with the European Union guidelines (2010/63/EU) and the Spanish Law (R.D. 53/2013 
BOE 34/11370-420, 2013) concerning the care and use of laboratory animals, and were approved by the 
Animal Experimentation Ethics Committee (EAEC/IEC) of University Hospital Virgen del Rocío/Institute of 
Biomedicine of Seville (IBIS).
Chromatin immunoprecipitation (ChIP). ChIP assay was performed using chromatin from fixed EPCs 
derived from mouse-NLBS (106) in 1% formaldehyde and was sonicated in a Bioruptor System (Diagenode, 
USA) which let us to obtain DNA fragments between 200 and 1000 bp in size. ChIP assay was performed with the 
Magna Chip HiSens Kit (Millipore,USA), according to manufacturer’s instructions and using the Anti-Dnmt3b 
antibody-ChIP Grade (Abcam, USA). 10% of samples volume/reaction was kept as controls (input) before 
immunoprecipitation. ChIP and input specimens were quantified by Quant-iT Picogreen dsDNA Assay Kit 
(ThermoFisher Scientific, USA).
Gene RefSeq Location Variants rs
Patient 
IDa Inheritance Phenotype
1000G_
MAF 
(phase 
3) ALL
1000G_
MAF 
(phase 
3) EUR
EVS_ 
MAF
ExAC_
MAF
MGP_
MAF
In silico 
prediction 
(SIFT /
Polyphen2)
BBX NM_020235
3:g.107466840  
C > T; exon
c.779C > T: 
p.Ala260Val rs150121801 3733
b Father S-HSCR 0.0012 0.002 0.0012 0.0026 NA T/B
3:g.107435532  
C > T; exon
c.241C > T: 
p.Arg81Trp rs142400819 4086 Mother
S-HSCR 
(Familial) 0.0030 0.007 0.0030 0.0028 0,006 D/D
SULF1 NM_015170 8:g.70541785_7054 1787delAAC; exon
c.2155_2157 
delAAC:p.
Asn 
720del
rs150178205 10943 Mother L-HSCR 0.0038 N 0.0045 0.0009 0,002 Neutral/-
RAB10 NM_016131
2:g.26257138  
C > T; UTR5 c.-340C > T rs112783454 4949 Father S-HSCR 0.0052 0.012
d N N 0,008
2:g.26257109_2625 
7110delGA;UTR5
c.-369_-368 
delGA rs745876590 4462
b Father S-HSCR Nc N N N NA
PPP2R2B NM_181674
5:g.145979904  
C > T; exon
c.1108G > A: 
p.Val370Ile rs369931023 3485 Father S-HSCR 0.0002 N 0.00008 0.00006 NA T/B
5:g.146017897 T >  
C; exon
c.905A > G: 
p.Asn302Ser rs150981315 3708 Father S-HSCR N N 0.0003 0.0004 NA D/B
5:g.145969279 G >  
C; UTR3 c.*231C > G rs141447016 3364 Mother L-HSCR 0.0038 0.007 N N NA
CDK5RAP2 NM_018249
9:g.123334309  
G > T; exon
c.70C > A: 
p.Pro24Thr 3606 Father S-HSCR N N N N NA T/B
9:g.123216045  
T > C; exon
c.2482 A > G: 
p.Lys828Glu rs549081765 8079 Mother S-HSCR 0.0004 N N 0.0002 NA T/B
9:g.123253661  
T > C; exon
c.1406 A > G:
p.Asn469Ser rs754779136 8079 Father S-HSCR N N N 0.000008 NA T/B
9:g.123287277  
G > A; exon
c.1079 C > T: 
p.Thr360Ile rs145165171 10943 Father L-HSCR 0.001 0.004 0.001 0.0009 0,002 T/B
Table 4. Rare variants identificated in exome sequencing from HSCR patients. apatients with two different 
variants are in bold. bVariants also present in one sibling. cN means variant not present in the database (1000 
Genomes, EVS, ExAC). dMAF > 0.01 in European population. NA: Not Available.
www.nature.com/scientificreports/
8SCIeNtIFIC RepoRts | 7: 6221 | DOI:10.1038/s41598-017-06539-8
Sequencing. ChIP and input samples were processed for subsequent sequencing with the ChIP-Seq DNA 
sample prep kit (Illumina, USA), following the manufacturer’s instructions. Size-selection was then performed 
by agarose gel electrophoresis to isolate fragments with size between 200 and 300bp. Afterwards, purified libraries 
were amplified by PCR and size range was subsequently checked in the Agilent 2100 Bioanalyzer using the High 
Sensitivity DNA Kit (Agilent, USA). Quantification was performed in the 7500-Real Time PCR System (Applied 
Biosystems) with the Library Quantification Kit (Kapa Biosystems). After proper dilutions, 4 nM libraries were 
processed, to obtain pools at a final concentration of 8 pM following the instructions of the Miseq Reagent kit V2. 
(50 cycles) (Illumina, USA). Finally we proceeded to sequence a total of 3 pools accounting for 12 ChIP and 12 
inputs in the MiSeq System (Illumina, USA).
Sequencing data analysis. After filtering, mapping was performed using Bowtie tool (mouse genome: 
mm9). MACS (Model-based Analysis of ChIP-Seq) algorithm was used for calling peaks, and BETA (Binding 
and Expression Target Analysis) minus software was applied to assign the ChIP-seq peak data to the neighboring 
genes (annotation). Such tools are available in the Galaxy and/or Galaxy/Cistrome platforms (https://usegal-
axy.org/; http://cistrome.org/ap/root). In combination with BETA minus, we also used PAVIS (http://manticore.
niehs.nih.gov/pavis2/) and PAPST tools, (https://github.com/paulbible/papst) to select and prioritize the candi-
date DNMT3b target genes.
Two different analyses were used to obtain a feasible and reliable number of Dnmt3b target genes. In the 
method 1, we merged all the FASTQ files from the ChIPs within the same pool and using the MACS software. 
Then through the BETA minus, PAVIS and PAPST tools we identified the genes located nearest to the regions 
represented by those peaks. Finally we selected the genes obtained after the analyses of at least 2 of the 3 softwares 
in at least 2 of the 3 pools. In the method 2, the peaks were identified with the MACS software using individually 
the FASTQ files from each ChIP within the same pool. Next, we applied the cluster tool to obtain the overlapping 
peaks and BETA and PAVIS software were used to identify the nearest genes. At last, we selected the genes that 
were identified in at least 2 of the clusters. Both methodological approaches are shown in a diagram in the Fig. 1.
All raw and peak data obtained in the study can be found in Gene Expression Omnibus (GEO), the following 
link has been created to allow review of record GSE92942 while it remains in private status: https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?token=yvmriecgjbyldqx&acc=GSE92942.
Identification of DNMT3b target genes in humans and their gene interaction. We have searched 
the Human Orthologs of the Dnmt3b target genes selected in mouse EPCs, by using the MGI database (http://
www.informatics.jax.org) that provides integrated genetic, genomic and biological data for the study of human 
health and disease. When the orthologs are unknown we used the BLAST (https://blast.ncbi.nlm.nih.gov/Blast.
cgi). Gene interactions of the DNMT3b target genes were obtained through the following parameters established 
by us in IPA tool: Genes and Chemicals; Interaction network (human, mouse, rat); Path designer; Overlay tool: 
Function & Disease: “Cellular development”. IPA led us to acquire of the interaction network of each DNMT3b 
target gene, where the genes involved in “cellular development” with a p-value cutoff of 0.05 were labeled.
Gene Expression Study by quantitative reverse transcription- PCR (RT- qPCR). We carried out 
a differential expression study of the resulting DNMT3b target genes previously identified in NLBs cultures, as 
well as of a set of genes related with them which were determined using the IPA tool. Finally we obtained 32 genes 
to assess their pattern expression in EPCs from both HSCR patients and controls. Purification and synthesis of 
cDNA were performed using the protocol provided by µMACS mRNA isolation Kit and µMACS cDNA Synthesis 
Kit in a thermo MAKSTM Separator (MACS Miltenyi Biotech, Germany) or RNAeasy Micro kit and RT2 First 
Strand kit (Qiagen, Germany). Expression studies were carried out in an Applied Biosystems 7900HT system 
(Life Technologies, USA) through the TaqMan® Array Plate (Life Technologies, USA) and SYBR Green meth-
ods (LincRNA and rRNA gene) (Bio-Rad, USA). Analysis was performed using the RQ Manager Software (Life 
Technologies, USA). 18S or GAPDH were used as endogenous controls respectively (Supplementary Table 1). 
Following the software recommendations, the upper limit of the cycle threshold (Ct) was set to be 32 for the 
TaqMan Array Gene Signature Plates and 35 for the SYBR Green assay. We considered positive expression exclu-
sively when Ct values were lower than such values.
Sequence variants analysis. In order to identify potential disease-causing variants in the genes selected 
after expression analysis, we used the data from a WES study previously published by our group13 that included 
56 HSCR patients comprising 39 sporadic and 17 familial cases. Single Nucleotide Variants (SNVs) and short 
insertions or deletions (Indels) were annotated using Annovar (hg19 Refgene) (http://wannovar.wglab.org/
index.php) and only those variants with a minor allele frequency (MAF) value < 0.01 in at least one databases 
(1000 Genomes, Exome Variant Server, Exome Aggregation Consortium or dbSNP) were selected. Additionally, 
the MAF was also checked in the 267 Spanish healthy phenotype exomes sequenced in the context of the 
Medical Genome Project40. The pathogenicity of SNVs was predicted by PolyPhen-2 (http://genetics.bwh.har-
vard.edu/pph2/) and SIFT (http://sift.bii.a-star.edu.sg) algorithms. Selected variants were further confirmed by 
Sanger sequencing.
Statistical analyses for gene expression study. Data are presented as the mean ± SEM (Standard 
Error Mean) of values obtained from at least three experiments. Comparisons between values obtained in 
Control-NLBs and HSCR-NLBs were analyzed using the Student’s t test. Differences were considered significant 
when p value ≤ 0.05.
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